The Unaudited Financial Results for the half year ended on 30.09.2025 is attached herewith for your reference.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Hamps Bio's board, at its meeting on November 14, 2025, approved the unaudited half-yearly results for H1 FY26 (April-September 2025). Revenue from Operations rose to about Rs 401.95 lakhs, up roughly 28% from Rs 312.86 lakhs in the same period last year. However, the company slipped into a deeper loss of about Rs 19 lakhs versus a small loss of Rs 1.5 lakhs in H1 FY25, as costs outpaced revenue growth. Operating cash flow was negative at Rs 32.59 lakhs, meaning the business spent more cash than it generated from operations. The statutory auditor MGHVS & Associates issued a clean (unqualified) limited review report with no qualifications. The company is investing heavily in capex for its FMCG division, with property, plant and equipment rising to Rs 391.29 lakhs from Rs 248.18 lakhs, funded largely by IPO proceeds and fresh borrowings.
For retail investors: revenue growth is encouraging but the widening losses and negative operating cash flow are yellow flags — the company is clearly in a build-out phase where costs are running ahead of earnings. Short-term stock reaction may be muted-to-negative given the deeper loss, though the clean audit opinion and ongoing IPO-funded expansion provide some support.